Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05996627 · ClinicalTrials.gov registry record · Phase 2

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

A Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Fred Hutchinson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
82
Enrollment target
4
Study locations

NCT05996627: Recruiting Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Fred Hutchinson Cancer Center.

NCT05996627 is a Phase 2 study of Chronic Graft Versus Host Disease that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 82 participants, below the 114-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (28% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05996627, a Phase 2 study of Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
82 participants
Enrollment target
4
Study locations

Study Summary

This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the need for starting additional immune suppressive medications.

Primary Outcome

Systemic therapies include any systemic agent given for a cGVHD indication, including extracorporeal photopheresis. Will use Gray's test. Point estimates of new systemic immunosuppressive use will be obtained using cumulative incidence estimates.

Conditions Studied

Chronic Graft Versus Host Disease

Interventions

  • PROCEDURE Biospecimen Collection
  • DRUG Belumosudil
  • OTHER Electronic Health Record Review
  • DRUG Placebo Administration

Study Locations (4)

Florida

  • Moffitt Cancer Center - Tampa

Massachusetts

  • Dana-Farber Cancer Institute - Boston

New York

  • Memorial Sloan Kettering Cancer Center - New York

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2023-12-06
Est. Completion 2028-11-30
Phase Phase 2
Fred Hutchinson Cancer Center

483 total trials

What NCT05996627 shows while recruiting

NCT05996627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 114-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (28% lower).

The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.

NCT05996627 reports a single indexed study location in Florida, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT05996627 about?

NCT05996627 is a clinical study titled "Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease". This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibi...

What is the current status of trial NCT05996627?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2023-12-06. Estimated completion is 2028-11-30.

What conditions does trial NCT05996627 study?

This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.

What interventions are being tested in trial NCT05996627?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Belumosudil (DRUG), Electronic Health Record Review (OTHER), Placebo Administration (DRUG).

Who is sponsoring clinical trial NCT05996627?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05996627 being conducted?

This trial has 4 study locations across Florida, Massachusetts, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Graft Versus Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05996627's enrollment target sits among peer trials

82 10th of 30 higher than 21 of 30 other Chronic Graft Versus Host Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Graft Versus Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03319901 · 82 participants · Phase 1

    Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

  • NCT03493425 · 82 participants · Phase 2

    Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

  • NCT04105270 · 82 participants · Phase 2

    RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

  • NCT04428658 · 82 participants · NA

    Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05996627

Source: ClinicalTrials.gov NCT05996627, the US trial registry maintained by the National Library of Medicine. NCT05996627 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.